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ABSTRACT 
 
Peripheral arterial disease (PAD) is a common atherosclerotic condition affecting 
the lower extremities. PAD patients share similar cardiovascular risk factors to 
coronary artery disease patients and suffer from increased cardiovascular 
morbidity and mortality. Statins have been widely used in coronary artery 
disease patients but have been underused in patients with PAD. In the current 
review, we present data which support the beneficial role of statins in both 
reducing cardiovascular events and improving symptom-related outcomes in 
PAD patients. Alongside their lipid lowering effects, their pleiotropic actions are 
also discussed. Recent guidelines, which strongly recommend the administration 
of statins in PAD patients, are also presented.  
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ABBREVIATIONS 
 
ABI – ankle-brachial index 
ACC/AHA – American College of Cardiology/ American Heart Association 
ADMA – asymmetric dimethylarginine 
apoA1 – apolipoprotein A1 
BH4 – tetrahydrobiopterin 
CAD – coronary artery disease 
CV-cardiovascular 
CBVD – cerebrovascular disease 
CLI – critical limb ischaemia 
CRP – c-reactive protein 
CVD – cardiovascular disease 
eNOS – endothelial nitric oxide synthase 
ESC – European Society of Cardiology 
ET-1 – endothelin 1 
FMD – flow mediated dilation 
FPP – farnesylpyrophosphate 
GGPP – geranylgeranylpyrophosphate 
HDL-c – high density lipoprotein cholesterol 
HMG-CoA –3-hydroxy-3-methylglutaryl-coenzyme A  
IC – intermittent claudication 
ICAM-1 – intercellular adhesion molecule 1 
IL-6 – interleukin 6 
IMT – intima media thickness 
LDL-c – low-density lipoprotein cholesterol 
MACE – major adverse cardiac events 
MPO – myeloperoxidase 
NADPH-oxidase – nicotinamide adenine dinucleotide phosphate oxidase 
NO – nitric oxide 
ox-LDL-c – oxidised low density lipoprotein cholesterol 
PAD – peripheral arterial disease 
PI3K-Akt – phosphatidylinositol-3 kinase/a serine threonine kinase 
PON-1 – paraoxonase 1 
RCT – randomised controlled trial 
ROS – reactive oxygen species 
SMC – smooth muscle cells 
SOD – superoxide dismutase 
TNF-α – tumour necrosis factor α 
VCAM-1 – vascular cellular adhesion molecule 1 
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INTRODUCTION 
 
Peripheral arterial disease (PAD) is a term most commonly used to describe an 
atherosclerotic condition in the lower extremities and is thought to be the third 
most common cause of cardiovascular (CV) morbidity and mortality. 
Epidemiological data has suggested that up to 202 million people globally may 
currently be living with PAD, with this figure increasing with age from ~ 6% at 
the age of 50 years up to > 20% at the age of 90 years (1).  
 
Although most PAD patients are asymptomatic, the predominant complication 
encountered in those who do report symptoms is that of intermittent 
claudication (IC) – a painful cramping of the leg typically brought on by exercise 
and occurring as a result of inadequate blood flow to the working muscle bed 
due to blocked or narrowed arteries. As the severity of the disease progresses, IC 
may develop into more serious complications such as leg ulcers, critical limb 
ischaemia (CLI), and the potential need for limb amputation. Even when 
asymptomatic, the presence of PAD (as most commonly identified by an ankle-
brachial index (ABI) < 0.9) remains a strong risk marker for accompanying 
atherosclerotic disease, with up to 56% of individuals with PAD in major trials 
found to have accompanying CAD or cerebrovascular disease (CBVD) (2,3). 
While these concomitant diseases are most likely driven by the same risk factors, 
there are limited data available about the impact of risk factor modification on 
morbidity and mortality in PAD patients (4).  
 
A range of different pharmacological therapies have been used for the treatment 
of PAD in order to both relieve symptoms and to slow atherosclerotic disease 
progression. HMG-CoA reductase inhibitors, more commonly known as statins, 
are among the most prescribed drugs in the world and are a cornerstone of CV 
disease management and treatment. Although the primary mechanism of statins 
is the lowering of cholesterol production through the competitive inhibition of 3-
hydroxy-3-methylglutaryl-coenzyme A reductase, it is now also clear that the 
inhibition of multiple other downstream pathways results in numerous 
pleiotropic effects which may act to further reduce atherosclerotic CV disease 
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risk over and above the lowering of LDL-c (5). While a wealth of research has 
provided evidence for the ability of statins to reduce CV risk in patients with 
established CAD and CBVD, much less attention has focused on their 
effectiveness in PAD patients.  
 
In this review, we will present data supporting the clinical benefit of statins both 
in relieving symptoms and improving CV outcomes in patients with PAD, and will 
discuss mechanistic pathways relevant to the pathophysiology of PAD that can 
be affected by statin use.  
 
STATINS AND CARDIOVASCULAR EVENTS IN PVD (Table 1) 
 
The largest study to date on the efficacy of statin therapy in peripheral vascular 
disease is that of the Heart Protection Study (HPS), a multi-centre randomised 
clinical trial of over 20,000 patients in which 6748 patients were identified as 
having PAD. In this study, 40mg of simvastatin daily over a median of 5 years 
was found to significantly reduce the occurrence of major CV events in patients 
with PAD by approximately one-quarter. The magnitude of this effect was similar 
to that seen in the trial population as a whole, was unaffected by whether 
patients had any record of prior myocardial infarction or CAD, and was evident 
even in those presenting with low levels of LDL-c prior to treatment (6). Another 
prospective observational study in a cohort of 660 elderly patients with 
symptomatic PAD and serum LDL-c levels > 3.23mmol/L confirmed these 
findings. With a mean follow-up of 39 months, those treated with statins had a 
relative risk ratio for new coronary events of 0.48 if they had suffered a previous 
myocardial infarction or 0.41 if they had not (7). Similar findings were also 
reported in a longer-term observational study looking at statin use in 2,420 
patients with an ABI < 0.9 who were followed for 8 years. This study showed a 
54% reduction in mortality in patients treated with statins after adjustment for 
all baseline variables and propensity scores (8).  
 
Expanding upon these findings, a number of studies have assessed the effect of 
more intense lipid-lowering therapy on both PAD incidence and long-term 
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mortality outcomes. Stoekenbroek and colleagues investigated the effect of high-
dose atorvastatin therapy vs. usual-dose simvastatin therapy in 8888 randomly-
allocated post-MI patients enrolled in the IDEAL trial, reporting a significantly 
lower hazard ratio for developing PAD (HR = 0.70) in the high-intensity group  
over a median 4.8 year follow-up. In addition, in those already suffering from 
PAD, the authors noted a significant reduction in overall CV and coronary events 
in the high-intensity group alongside significantly fewer coronary 
revascularisations (9). A separate study, investigated the effect of intensified 
lipid-lowering therapy on long-term mortality outcomes in relation to LDL-c 
levels and reported that further lowering of LDL-c was associated with reduced 
all-cause mortality and higher statin doses were also associated with improved 
outcomes overall (10). These results have been supported by the data of a 
Cochrane meta-analysis on 17 lipid lowering trials, revealing a 26% reduction of 
CV events in patients treated with statins – mostly due to reduction in the 
incidence of coronary events (11). Although a number of lipid lowering drugs 
were assessed, the most consistent benefits on CV mortality and morbidity were 
shown with statins, particularly simvastatin when used in patients with high 
cholesterol levels (>3.5mmol/L).  
 
STATINS AND SYMPTOM-RELATED OUTCOMES IN PAD (Table 2) 
 
Irrespective of their effect on CV mortality, the use of statins in PAD patients has 
been associated with improvement in clinical symptoms – i.e. symptoms of IC, 
improvement in walking distance, and outcomes following vascular 
interventions/surgery. This was first evidenced in a sub-analysis of the 
aforementioned 4S study, where a 38% reduction in the risk of new or 
worsening intermittent claudication and a 48% reduction in new or worsening 
carotid bruits was reported in patients assigned to simvastatin treatment and 
who were followed up for a median of 5.4 years (12).  
A number of additional studies from the early 2000s further supported this 
positive effect of different statins on IC and walking distance. Mohler and 
colleagues randomised 354 patients with PAD and IC to receive either placebo, 
10mg or 80mg atorvastatin daily for 12 months and noted a significant increase 
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in community based physical activity (as assessed by questionnaire) in both 
groups as well as increased pain-free walking time in the 80mg statin group 
(63% vs. 38% increase) when compared to placebo at 12 months (13). Similar 
results were subsequently reported in patients taking 40mg simvastatin daily, 
with a 24% and 42% increase in exercise-induced time to onset of claudication 
at 6 and 12 months respectively (14). Likewise, in 86 hypercholesterolaemic 
patients randomised to 40mg simvastatin daily or placebo for 6 months, those in 
the statin group had improvements in pain-free walking distance, total walking 
distance, ankle-brachial index, and symptoms of claudication (15). These 
beneficial actions of statins in reducing morbidity in PAD patients are thought to 
occur due to mechanisms over and above their primary lipid-lowering actions. 
For instance, in a study where lower-extremity function was investigated in 392 
patients both with and without PAD, individuals on statins had superior leg 
functioning compared to those who did not receive statin and this effect was 
independent of cholesterol levels. These findings suggest that other mechanisms 
such as decreased inflammation and improved endothelial function may account 
for the improvement in performance noted in PAD patients (16). 
 
In patients with more advanced forms of lower-extremity PAD requiring surgical 
intervention or limb amputation, there is also good evidence for the ability of 
statins to reduce post-operative mortality risk (17–21). Results on local events 
such as restenosis, graft patency and limb salvage, however, come 
predominantly from retrospective reviews, and are therefore less clear. In those 
undergoing arterial reconstructions, statins have been shown to improve 
patency of autogenous infrainguinal bypass grafts in some (22,23) but not all 
studies (19). Data involving the effects of statins on restenosis following surgical 
interventions is limited, although a retrospective review of 218 patients 
undergoing either endovascular interventions or bypass grafts has suggested a 
beneficial effect of statin use in these individuals (24)  Beneficial findings have 
also been  reported in a number of studies involving patients presenting with 
CLI, with those on statins found not only to have lower rates of overall mortality 
and major adverse cardiovascular events, but also to have improved limb salvage 
and amputation-free survival outcomes (18,20,23,25). Similar to findings 
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surrounding graft patency, however, these outcomes have not been consistently 
reproduced in all studies, and warrant further investigation (17,19). 
 
ANTI-ATHEROSCLEROTIC EFFECTS OF STATINS IN PAD  
 
 Pathophysiology of atherosclerosis (Figure 1) 
 
The prevailing theory of atherogenesis involves lipid retention and oxidation 
within the vessel wall in response to a compromised endothelium, and therefore 
the primary beneficial effect of statins is commonly attributed to their ability to 
lower LDL cholesterol levels, slowing atherosclerotic progression and leading to 
regression of established atheroma. Alongside lipid retention, however, multiple 
other inflammatory, oxidative, and proliferative pathways contribute to the 
complex atherosclerotic process. The accumulation of modified lipid particles 
within the sub-intimal space triggers an innate inflammatory response, further 
activating endothelial cells and stimulating the secretion of adhesion molecules 
(e.g. ICAM-1, VCAM-1), reactive oxygen species (e.g. superoxide) and numerous 
pro-inflammatory cytokines and chemokines (e.g. CRP, TNF-α, IL-6) which act to 
draw monocytes and lymphocytes into the vessel wall. Upon entry, monocytes 
differentiate first into macrophages and then, after the uptake of oxidised lipids, 
into foam cells. Over time, smooth muscle cells (SMCs) proliferate in the lesion 
due to both migration from the tunica media and also division of existing muscle 
cells within the intima itself. The production of interstitial collagen and elastin by 
these cells results in the formation of a fibrous cap overlying a lipid-rich necrotic 
core, the latter of which is formed from the apoptosis of SMCs and lipid-laden 
macrophages and subsequent release of their contents. Once established, these 
atherosclerotic plaques are common causes of major CV events such as 
myocardial infarction or stroke, and may contribute to the symptoms 
experienced in PAD.  
 
 
 Statins and lipid profiles in PAD 
 
 9 
While the lipid profile of patients with PAD is commonly that of the metabolic 
syndrome, comprising of high triglyceride levels and low HDL cholesterol, 
alteration in these lipid fractions has been studied less than the effect of 
lowering the LDL cholesterol. Statins lower LDL primarily through the inhibition 
of the HMG-CoA-reductase enzyme, which catalyses the first step of cholesterol 
synthesis in the mevalonate pathway. This inhibition results in up-regulation of 
LDL receptor on the hepatocyte membrane, thereby increasing uptake of LDL 
particles from the plasma. While the ability of newer statins to lower LDL by up 
to 50% is well known (26), they have also been shown to decrease triglyceride 
levels to a lesser degree (up to 20%), presumably through the inhibition of its 
synthesis in the liver and enhancement of lipoprotein lipase enzyme activity in 
the adipocytes (27).  
Statins have also been shown to increase levels of high density lipoprotein (HDL) 
by up to 10%, but the precise mechanism of this effect is unclear. HDL inhibits 
the progression of the atherosclerotic process by facilitating the reverse 
transport of cholesterol from lipid laden monocytes in the vascular wall and also 
by modulating the inflammatory response (28). The HDL-raising properties of 
statins may result from the induction of the apolipoprotein-A1 (apoA1) gene 
through the activation of peroxisome proliferator-activated receptors (29). 
However other pathways, affected by statins, might contribute to improvement 
not only in the levels but also in the function of HDL. HDL can become 
dysfunctional and pro-atherogenic in the presence of increased oxidative stress 
which is commonly seen in patients with PAD (30). Increased levels of 
myeloperoxidase (MPO), a key generator of oxidative stress, has been associated 
with increased CV risk in PAD patients(31) and statins can reduce oxidative 
stress by reducing both MPO activity (32) but also increases in PON-1 
activity(33).  
 
 Statins and plaque stabilisation/regression in PAD 
 
Clinical studies have shown that the improvement in lipid profile observed 
following statin therapy is associated with a halt in the progression or even 
regression of atherosclerosis in PAD. Numerous studies have reported a slowing 
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or regression of intimal-medial thickening (IMT) – a commonly used surrogate 
marker for atherosclerotic disease progression – in various vascular beds 
following statin treatment. In the carotid artery, multiple studies have reported 
beneficial changes in IMT in patients with established CV risk factors such as 
hypercholesterolemia (34–36) or hypertension (37). In the Kuopio 
Atherosclerosis Prevention Study (KAPS), this effect was found to occur even in 
individuals at low overall risk of atherosclerotic disease and was observed to be 
greater in smokers than non-smokers (36). Similar results have been reported in 
the superficial femoral artery, a site particularly prone to the development of 
lower-extremity PAD (38,39), and have been shown to be visible in as early as 4-
8 weeks following statin treatment, which suggests the contribution of non-lipid-
lowering mechanisms to the observed response (38). These changes appear to 
follow a dose-response pattern, with more aggressive therapy promoting IMT 
regression. For example, in type 2 diabetic patients – a population at increased 
risk of PAD – two years of cerivastatin or simvastatin treatment showed no effect 
on cIMT progression (40). In a later study assessing a similar population, 
however, although standard lipid lowering treatment had no effect on cIMT 
progression (0.039mm increase over 3 years), more aggressive lipid lowering 
(LDL lowered by ~ 30 mg/dl) therapy was found not only to slow progression, 
but to result in a significant regression of cIMT of 0.012mm when used alone, or 
0.025mm when combined with ezetimibe (41).  
Similar results have been reported for established atherosclerotic plaques. Statin 
treatment has been shown to reduce plaque volume and prevent acute, unstable 
coronary events through stabilisation of the “vulnerable plaque”. Statins have the 
ability to improve the stability of these vulnerable plaques through the depletion 
of lipid levels; inhibition of LDL oxidation, inflammation, smooth muscle cell 
proliferation and apoptosis; and increase in collagen content within the plaque 
itself (42). In support of this, previous imaging studies have shown the slowing 
of PAD progression, when statin was administered over a 2 year period, in men < 
70 years old with established CAD, serum cholesterol levels of 155 – 310 mg/dl, 
and triglycerides < 354 mg/dl (39). Similar results have also been observed 
following low dose atorvastatin treatment (20mg/day), with reduction in 
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femoral artery IMT being observed within as little as 4 weeks from initiation of 
treatment (38).  
 
 Pleiotropic effects of statins in PAD 
 
Although the primary mechanism of statins is the lowering of cholesterol 
production, it is now also clear that the inhibition of multiple other downstream 
pathways results in numerous pleiotropic effects which may act to further 
reduce atherosclerotic CVD risk over and above the lowering of LDL-c (5). This is 
especially pertinent in PAD, given that the association between plaque 
size/stability and symptoms is less clear than that encountered in CAD. With 
evidence suggesting that the predominant PAD symptom of IC may be more 
closely linked to factors such as inflammation, endothelial dysfunction, skeletal 
muscle adaptations, and mitochondrial dysfunction rather than simply the 
presence of a flow-limiting lesion within the vessel lumen (15), the pleiotropic 
effects of statins in this population may offer benefits over and above that caused 
by lipid lowering alone. 
 
Statins and endothelial function in PAD 
 
Endothelial dysfunction underlies every stage of atherosclerotic disease and 
numerous studies have demonstrated disturbed endothelial physiology in 
patients suffering from peripheral vascular disease, measured both invasively 
via vasodilator infusion (43,44) and non-invasively via flow-mediated dilation 
(FMD) of the brachial artery (45). Furthermore, inverse relationships between 
PAD severity and endothelial function have been observed when comparing PAD 
patients with age- and sex-matched controls, with FMD in symptomatic PAD 
being less than half that of healthy equivalents (5.1% vs. 11.7%) (45). Similar 
findings have been reported in a study of 199 patients presenting for elective 
vascular surgery and subsequently followed for 1.2 years, with significantly 
lower FMD reported in patients who experienced a major cardiovascular event 
than those who did not (4.4% vs. 7%) (46). Although the mechanisms by which 
statins can affect the endothelium in the setting of PAD have not been explored, 
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it is reasonable to believe that statins can affect similar pathways to those 
reported in CAD patients or in individuals who share the same risk factors as 
PAD patients.  
 
The effect of statins on endothelial function was initially thought to be simply 
related to its lipid lowering actions (47). For instance, a study in patients with 
known CAD has previously reported a sustained improvement in FMD over 10 
months which occurred in combination with a lowering of LDL-c levels by ~ 25% 
following statin therapy(48). Similar improvements have also been observed in 
hypercholesterolaemic men following eight weeks of simvastatin treatment (49), 
while cessation of the same statin for 6 weeks had the opposite effect (50). 
Furthermore, a single session of LDL apheresis has previously been shown to 
acutely improve endothelial function (51), and in vitro studies have 
demonstrated the ability of oxidised LDL to reduce endothelial nitric oxide (NO) 
release (52). However, numerous studies have demonstrated that statins may 
exert additional beneficial endothelial effects through alternative pathways (53). 
Seminal work by Laufs and colleagues supported this hypothesis by showing the 
ability of statins to exert direct effects on endothelial NO synthesis and 
bioavailability through the upregulation of endothelial nitric oxide synthase 
(eNOS)(54). These effects are likely to be mediated through the ability of statins 
to block the synthesis of isoprenoid intermediates such as 
farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP), 
molecules which lie on the same metabolic pathway as that responsible for 
cholesterol synthesis and are therefore simultaneously affected by HMG-CoA 
reductase inhibition (55). Furthermore, activation of a separate 
phosphatidylinositol-3 kinase/Akt (PI3K-Akt) mediated pathway has also been 
reported following statin treatment (56), providing yet another alternative 
pathway for eNOS activation. Statins can also increase NO synthesis by lowering 
plasma levels of asymmetric dimethylarginine (ADMA)-an endogenous inhibitor 
of nitric oxide synthesis- which is upregulated in PAD patients and has been 
shown to predict risk of major adverse cardiovascular events (MACE)(57)(58).  
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In addition to their beneficial effects on NO bioavailability, statins have also been 
shown to affect circulating levels of numerous other vasoactive peptides 
produced by the endothelium. Endothelin-1 (ET-1) is a potent vasoconstrictor 
implicated in the pathophysiology of PAD (59,60) and has been shown in a 
recent meta-analysis of 15 RCTs to be significantly lowered following statin use 
(weighted mean difference of - 0.30 pg/ml) when compared to placebo (61). This 
decrease is thought to be related to the down-regulation of prepro-endothelin-1 
mRNA via Rho protein-associated pathways (62,63), and is maintained even in 
the presence of ox-LDL (62). In addition to reducing ET-1 synthesis, statins may 
also exert additional beneficial effects through the attenuation of vascular 
smooth muscle responsiveness to ET-1 vasoconstriction, as shown by the ability 
of simvastatin to exert a concentration-dependent relaxation of isolated aortic 
rings pre-contracted with ET-1 (64).  
 
Anti-inflammatory effects of statins in PAD 
 
Increased inflammatory markers are associated with both intermittent 
claudication and increased CV mortality in patients with PAD. A nested case-
control study carried out in 1998 as part of the Physicians Health Study was one 
of the first major studies to specifically investigate the association between C-
reactive protein (CRP) and future risk of developing symptomatic PAD (65), and 
found that median CRP levels were not only significantly higher in participants 
who developed PAD, but that the relative risk of future complications increased 
in line with baseline CRP concentration. These findings were replicated in a 
cohort of 475 women in the RATIO study (66), and in the Edinburgh Artery 
Study, in which CRP was found to be related to PAD severity in a cohort of over 
1500 individuals (67). After 12 years of follow-up in the latter study; the 
inflammatory markers CRP, interleukin-6 and intercellular adhesion molecule -1 
were all shown to be associated with the progression of atherosclerotic disease, 
even after adjustment for other CV risk factors. Although these effects may occur 
due to a lowering of inflammatory ox-LDL within the vascular wall, a wealth of 
evidence also exists to suggest additional anti-inflammatory effects of statins 
that occur over and above their LDL-lowering properties and that these are 
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mediated through mechanistic pathways lying downstream of HMG-CoA 
inhibition. The PRavastatin Inflammation/CRP Evaluation (PRINCE) trial, 
conducted in 2001, was the first major trial to investigate whether the 
pleiotropic properties of statins could reduce inflammation independent of their 
cholesterol-lowering properties in a normolipidaemic population (68). In this 
randomised, placebo-controlled, double-blind clinical trial, 1702 individuals with 
no prior history of CVD were assigned to receive 40 mg/d pravastatin or placebo 
for 24 weeks, with the changes in CRP and cholesterol assessed at both baseline 
and end of study. At the half-way point of the study, a decrease in CRP levels was 
already evident in the statin group (14.7% reduction), and this was maintained 
until the end of the study (16.9% reduction). These changes were independent of 
the statins effect on LDL-c, and were subsequently replicated in a second open-
label trial carried out by the same investigators (68). Similarly, in the JUPITER 
trial, 20 mg/daily rosuvastatin for 1.9 years was shown to reduce CRP by 37% in 
patients who presented with normolipidaemia (< 130 mg/dl) but elevated CRP 
levels (> 2.0 mg/l) (69). Likewise, in a secondary prevention trial involving PAD 
patients, patients receiving statin therapy had significantly lower levels of 
numerous inflammatory markers when compared to controls (70).  
 
Statins and oxidative stress in PAD 
 
Patients with established PAD exhibit higher levels of oxidative stress when 
compared to healthy controls (71), with this increase occurring due to a 
combination of both increased reactive oxygen (ROS) production and decreased 
antioxidant enzyme activity. ROS can be produced at multiple sites within the 
vascular wall via pathways such as NAD(P)H oxidase, xanthine oxidase, 
myeloperoxidase, eNOS uncoupling, a dysfunctional electron transport chain, 
and the activation of macrophages and T-cells (72,73). Under normal 
physiological conditions, the production of these free radicals is balanced by 
endogenous antioxidant activity such as superoxidase dismutase (SOD) and 
glutathione reductase, preventing their accumulation and subsequent generation 
of oxidative stress. This balance is disrupted in PAD leading to an excess of 
reactive oxygen species and chronic oxidative stress.  
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Statins have been shown to reduce oxidative stress by decreasing the expression 
and activation of key enzymes such as NADH/NADPH oxidase and xanthine 
oxidase. Atorvastatin therapy in normocholesterolaemic hypertensive rats 
resulted in improved endothelial function in line with a decrease in ROS (62% of 
control), a decrease in expression of the NAD(P)H oxidase subunit p22phox 
(63% of control), and an upregulation of eNOS mRNA expression and activity 
(74). In human studies, the assessment of gp91phox mRNA expression (a 
substrate-binding unit of endothelial NADPH oxidase) in internal mammary 
artery biopsies of patients both on and off statins has indicated the presence of a 
decreased level of vascular NAD(P)H-oxidase expression and superoxide 
formation only in the arteries extracted from statin patients (75). Although lipid-
lowering per se can contribute to a reduction in oxidative stress (76), statins also 
appear to be able to further reduce ROS production through a separate NADPH-
oxidase inhibitory pathway. Long-term rosuvastatin treatment in mice has been 
shown to decrease superoxide production through an NADPH-oxidase pathway 
(77), while atorvastatin treatment in hypercholesterolaemic patients displays a 
dose-dependent reduction in isoprostanes from as early as 3 days administration 
(78). Statins have also been shown to reduce superoxide formation from human 
monocyte-derived macrophages (79).  
 
In vitro work has demonstrated the ability of cerivastatin to not only upregulate 
eNOS expression, but also to increase tetrahydrobiopterin (BH4) synthesis in 
endothelial cells through an upregulation of GTP-cyclohydrolase I gene 
expression (80). Similarly, in clinical studies, in patients undergoing coronary 
artery bypass surgery, pre-treatment with atorvastatin 3 days prior to surgery 
resulted in an increase in vascular BH4 and a corresponding decrease in 
superoxide production prior to any changes in lipid levels (81). As well as 
reducing oxidative stress through inhibition of ROS generating pathways, statins 
have also been shown to exert further reductions in oxidative stress by 
promoting antioxidant pathways, as evidenced by the ability of simvastatin to 
up-regulate superoxide dismutase activity in hypertensive rats (82). 
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GUIDELINES FOR THE USE OF STATINS IN PAD 
 
A number of studies have provided strong evidence about the beneficial role of 
statins in patients with PAD. The European Society of Cardiology (ESC) 
guidelines for the diagnosis and treatment of PAD recommend a target LDL-C 
below 100mg/dl and optimally below 70mg/dl (Class I recommendation) in all 
patients with PAD regardless of baseline LDL-C levels. When the target level 
cannot be reached, a reduction of >50% in LDL-C should be attempted (83). 
These recommendations are similar to those of the American College of 
Cardiology/ American Heart Association (ACC/AHA), who suggest a target for 
LDL-C level <100mg/dl (Class I recommendation) in all patients with PAD and 
LDL level <70mg/dl for patients at very high risk of ischaemic events (Class IIa 
recommendation). For patients with PAD and high triglycerides/low HDL but 
normal LDL, ACC has an additional Class IIa recommendation for the use of fibric 
acid derivatives (84). According to 2013 ACC/AHA guidelines moderate or high 
dose statin therapy is advocated in all symptomatic PAD patients to reduce the 
risk of CV events (85). For the management of PAD patients who are undergoing 
non-cardiac vascular surgery, the 2014 ACC/AHA guidelines also recommend the 
initiation of statin therapy, irrespective of their underlying risk factor profile,  for 
reduction in the  incidence of CV events (Class IIa recommendation) (86). 
 
Although a threshold for LDL-C is recommended by the guidelines, there are still 
questions as to how intensive statin therapy should be, as side effects such as 
myopathy, liver damage, and an increased risk of type 2 diabetes are all well-
recognised risks with this medication. In support of intensive statin therapy in 
PAD, higher statin doses have been shown not only to reduce CV events in 
patients with pre-existing PAD (10), but also to reduce the incidence of PAD in 
primary prevention (9). Two large scale meta-analyses have attempted to clarify 
the threshold at which the possible benefits of statins are outweighed by their 
adverse effects. Although high-dose statin therapy was found to provide 
substantial clinical benefit when compared to low-dose therapy and placebo, 
both studies reported an accompanying increase in the risk of adverse events in 
the intensively treated group (87,88). These events, however, were found to 
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consist predominantly of non-urgent conditions such as myalgia or liver enzyme 
elevations, with serious events remaining rare and not differing significantly 
between the high-dose and placebo groups (88).This increase in risk appeared to 
be significantly outweighed by its clinical benefits, however, with data 
suggesting a reduction in CV events of 37 per 1000 patients, as opposed to the 
appearance of only 5 adverse events in the same number of subjects. Similar 
findings have also been reported from the JUPITER trial, in which a reduction in  
all-cause mortality was observed in 20% of patients receiving rosuvastatin and 
in 46% of patients that attained target levels of LDL-C<50mg/dl over a median 
period of 2 years (89). Notably in this trial, the rate of adverse effects was again 
similar in the placebo and statin groups (except for muscle symptoms). These 
findings strongly suggest that the benefits of intensive statin treatment outweigh 
the possible adverse effects, particularly in high-risk patients.  
 
While there is limited evidence regarding the monitoring of lipid lowering 
treatment, the ESC recommends a first assessment of the response to therapy at 
8+/-4 weeks following initiation of statin treatment and thereafter annual follow 
up monitoring once the patient has reached the lipid lowering targets (83). 
Furthermore, while there is no clear evidence of a high risk of adverse effects of 
low LDL-C levels, the ACC guidelines recommend decreasing statin dosage if two 
consecutive values of LDL-C are below 40mg/dl (84).  
 
As previously mentioned, moderate doses of statin therapy have been associated 
with myopathy, liver disease, increased incidence of diabetes development and 
cognitive impairment.  In randomized clinical trials, however, myalgia - the most 
common adverse effect following statin use – has shown similar presentation in 
both statin and placebo groups (90). The European Atherosclerosis Society 
consensus panel recommends that, in the presence of muscle pain or weakness, 
creatine kinase levels should be obtained and, in case that the levels are elevated, 
statins should be discontinued and subsequently restarted at a lower dose. The 
American Academy of Family Physicians on the other hand offers a Class C 
recommendation and only in patients at high risk of muscle toxicity baseline 
creatine kinase levels should be obtained (91). Overall, the side effects reported 
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with statin use in PAD patients are rare and, for most patients, the risk-to-benefit 
calculation involving these adverse effects favours statin use.  
 
 
 
CONCLUSIONS 
 
Peripheral vascular disease is under-diagnosed and is a major risk factor for CVD 
morbidity and mortality. Despite the high prevalence of atherosclerotic risk 
factors in those suffering from the disease, PAD patients receive less intensive 
treatment than those diagnosed with CAD (2) and have a long-term prognosis 
that is significantly worse (92). A wealth of evidence exists for the ability of 
statins to exert beneficial effects on numerous pathophysiological pathways that 
underlie every stage of the disease, and clinical evidence from large-scale 
observational studies and randomised control trials provide strong evidence for 
their ability to significantly diminish morbidity and mortality. Better screening 
for PAD and improved pharmacological interventions with drugs such as statins 
are likely to improve outcomes and help to reduce the significant health and 
financial burdens associated with this prevalent disease.  
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TABLE LEGENDS 
 
 
Table 1: Statin use in PAD and CV outcomes  
 
Abbreviations: RCT, randomised controlled study; CLI, chronic limb ischaemia; 
OR, odds ratio; HR, hazard ratio; PAD, peripheral arterial disease; LDL, low 
density lipoprotein; ACE, angiotensin converting enzyme; MI, myocardial 
infarction; MACE, major adverse cardiac events; RCT, randomized controlled 
trial; Rx, treatment; CV, cardiovascular 
 
 
Table 2: Statin use in PAD and symptom-related outcomes 
 
Abbreviations: RCT, randomised controlled trial; PAD, peripheral arterial 
disease; MI, myocardial infarction 
 
 
 
FIGURE LEGEND 
 
 
Figure 1: Pathways in the atherosclerotic process that may be affected by 
statin use 
 
Alongside its primary lipid-lowering action, the blocking of multiple pathways 
downstream of HMG-CoA reductase pathway with statin use results in a number 
of pleiotropic effects that may additionally contribute to a reduction in 
atherosclerotic risk in PAD patients. These pathways have been shown to affect 
every stage of the disease process from the initial development of endothelial 
dysfunction to the stabilisation of vulnerable established plaques. The arrows 
demonstrate pathways that can be affected by statin use.  
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Table 1: Statin use in PAD and CV outcomes 
Author/ Year Study type Study group Statin / follow up CV Outcome 
HPS 2002 
(6) 
RCT 20536 adults 40-80 years with 
CAD, occlusive arterial disease or 
diabetes 
Simvastatin 40mg/d  vs 
placebo 5 year follow up 
Reduced  all-cause mortality in simvastatin 
group 
HPS 2007 
(93) 
RCT 6748 patients with PAD and 13788 
other high risk patients 
Simvastatin 40mg/d vs 
placebo for mean of 5 years 
Reduction in first major vascular event by 
25% and that of peripheral vascular events 
by 1/6 in simvastatin group 
Aronow & Ahn  
2002 (7) 
Prospective 
follow up study  
264 men and 396 women mean 
age 80+/-9 years with PAD and 
LDL>125mg/dl . Among those 318 
were on statin and the remaining 
on no lipid lowering treatment 
90% of 318 patients who 
were treated with statins 
were on simvastatin 20-
40mg/d, 9% with pravastatin 
40mg/d and 1% with 
lovastatin 40mg 
Significant reduction in incidence of 
coronary event in those treated with statins.  
Schillinger et al 
2004 (70) 
Prospective 
observational 
study 
515 patients with severe PAD 
(median age 70 years). 52% were 
on statin 
No statin type or dose 
specified/ median follow up 
21 months 
Statin Rx was associated with improved 
intermediate-term survival only in PAD 
patients with high inflammatory activity 
Feringa et al 2006 
(8) 
Prospective 
observational 
study 
2420 PAD patients (64+/_11 yrs) No statin dose or type 
specified/ median follow up 
8 years 
Statins, beta blockers, aspirin and ACE 
inhibitors are associated with reduction in 
long term mortality in PAD patients 
Feringa et al 2007 
(10) 
Prospective 
observational 
study 
1374 PAD patients (61+/-10 
years) 
Simvastatin, pravastatin, 
fluvastatin, atorvastatin and 
rosuvastatin/ mean follow up 
6.4+/-3.6 yrs 
Higher doses of statins and lower LDL 
cholesterol are independently associated 
with improved outcome in PAD patients 
Stoekenbroek et 
al 2015 (9) 
RCT 8888 post myocardial infarction 
patients  
Atorvastatin 80mg/d vs 
simvastatin 20-40mg/d/ 
median follow up 4.8 years 
High dose atorvastatin reduced the 
incidence of PAD and incidence of coronary 
events compared to simvastatin 
Antoniou et al 
2014 (94) 
Systematic 
review-meta-
analysis 
12 observational cohort studies 
and 2 RCT in 19368 patients 
 Decreased all-cause mortality 
(HR:0.77[0.68-0.86] and incidence of stroke 
(OR:0.77[0.67-0.89] and trend towards 
improved CV mortality in statin users 
De Martino et al 
2016 (95) 
Retrospective 
review from 
Vascular 
3039 patients who underwent 
elective suprainguinal repair  
8323 had infrainguinal bypass 
Antiplatelet and statins Preoperative statin and antiplatelet Rx were 
not associated with improved rated of in-
hospital MI/death after major open vascular 
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Quality 
Initiative 
database 
3007 had open infrarenal 
abdominal aortic aneurysm repair 
operations. 
Schanzer et al 
2008 (19) 
Observational 
study 
1404 patients with CLI who were 
randomized to test the efficacy of 
edifoligide for the prevention of 
graft failure 
45% were on statins 
59% were on beta-blockers 
and 80% were on antiplatelet 
drugs 
Perioperative MACE and early mortality 
were not affected by the use of any drugs. 
Statin use was associated with improved 
survival in CLI patients 1 year after surgical 
revascularization 
Suckow et al 2015 
(17) 
Observational 
study 
2067 patients man age 67+/-11 
years with CLI who underwent 
infranguinal bypass from 2003-
2011 (Vascular Study group of 
New England registry) 
74% were on statins 
perioperatively and at 1 year 
follow up 
Statin therapy is associated with 5 year 
survival benefit. However, 1 year limb 
related outcomes were not influenced by 
statins.  
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Table 2: Statin use in PAD & symptom-related outcomes  
 
Author Study type Patients Medication/ Follow up Symptom-related outcomes 
Pedersen et al 1998 (12) RCT 4,444 patients with prior 
MI and serum cholesterol 
5.5 – 8 mmol/L 
Simvastatin 20 or 40 mg/d vs. 
placebo for median 5.4 years 
Statin treatment associated with 38% 
reduced risk of new or worsening IC 
and 48% reduced risk of new or 
worsening carotid bruits compared to 
placebo.  
Mohler et al 2003 (13) RCT 354 patients with 
claudications 
Atorvastatin 10mg/d or  
80mg/d vs. placebo for 12 
months 
The 80mg atorvastatin group 
improved pain free walking distance 
by 63% vs 38 % in the placebo. There 
was no difference between 10mg 
atorvastatin and placebo 
Aronow et al 2003 (14) RCT 69 patients with PAD Simvastatin 40mg/d vs 
placebo 
Increase in treadmill exercise time of 
24% at 6 months and 42% at 12 
months in simvastatin group 
compared to placebo 
Mondillo et al 2003 (15) RCT 86 patients with PAD Simvastatin 40mg/d vs 
placebo 
Simvastatin group was associated with 
significant increase in 90meters pain 
free walking distance compared to 
placebo 
McDermott et al 2003 (16) Prospective 
observational 
study  
392 PAD patients Statins, aspirin, beta blocker, 
ACE inhibitors and 
vasodilators 
Statins were associated with superior 
leg functioning independent of 
cholesterol levels compared to no 
statin use 
Khumbani et al 2014 (18) Retrospective 
review 
5,861 patients with 
symptomatic PAD 
62.2% on statins at baseline 
(74.5% in patients with 
concomitant CAD and 64.0% 
in patients with concomitant 
CBVD) with 4 year follow-up 
Statins were associated with 18% 
lower rate of adverse limb outcomes 
(worsening symptoms, peripheral 
revascularisations, ischaemic 
amputations) at 4 years 
Westin et al 2014 (20) Retrospective 
review 
380 CLI patients following 
diagnostic angiography or 
endovascular 
intervention 
65% on statins 
perioperatively with median 1 
year follow-up 
Statins were associated with increased 
amputation-free survival and lower 
rates of mortality and MACE 
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Abbruzzese et al 2004 (22) Retrospective 
review 
172 PAD patients 
undergoing autogenous 
infrainguinal 
reconstructions 
49.7% of patients on statins at 
time of procedure with 2 year 
follow-up 
Statin therapy associated with 
improved graft patency. Risk of graft 
failure 3.2x higher in control group. 
Aiello et al 2012 (23) Retrospective 
review 
646 patients with PAD 
undergoing endovascular 
intervention for CLI 
49.4% of patients on statins at 
time of procedure with 2 year 
follow-up 
Statins associated with improved 
primary and secondary patency, limb 
salvage rates, and overall survival 
Siracuse et al 2012 (24) Retrospective 
review 
218 patients undergoing 
their first intervention for 
claudication due to 
superficial femoral artery 
disease 
Statin use at baseline in 62% 
of patients undergoing lower 
extremity bypass and 69% of 
patients undergoing 
percutaneous transluminal 
angioplasty ± stent 
Statin therapy improved overall 
freedom from stenosis and symptom 
recurrence. No differences observed in 
3 year mortality. 
Henke et al 2004 (25) Retrospective 
review 
293 patients undergoing 
infrainguinal bypass, 
predominantly for limb 
salvage 
Statins, ACE inhibitors, and 
antiplatelet agents or warfarin 
Statin therapy associated with 
improved graft patency and limb 
salvage 
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Figure 1: Pathways in the atherosclerotic process that may be affected by statin use 
